Adherence and Discontinuation of Optimal Heart Failure Therapies According to Age: A Danish Nationwide Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Adherence and Discontinuation of Optimal Heart Failure Therapies According to Age : A Danish Nationwide Study. / Garred, Caroline H.; Zahir, Deewa; Butt, Jawad H.; Ravn, Pauline B.; Bruhn, Jonas; Gislason, Gunnar H.; Fosbøl, Emil L.; Torp-Pedersen, Christian; Petrie, Mark C.; McMurray, John J.V.; Køber, Lars; Schou, Morten.
In: Journal of the American Heart Association, Vol. 11, No. 19, e026187, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Adherence and Discontinuation of Optimal Heart Failure Therapies According to Age
T2 - A Danish Nationwide Study
AU - Garred, Caroline H.
AU - Zahir, Deewa
AU - Butt, Jawad H.
AU - Ravn, Pauline B.
AU - Bruhn, Jonas
AU - Gislason, Gunnar H.
AU - Fosbøl, Emil L.
AU - Torp-Pedersen, Christian
AU - Petrie, Mark C.
AU - McMurray, John J.V.
AU - Køber, Lars
AU - Schou, Morten
N1 - Funding Information: Garred reports lecture fees from Astra Zeneca. Dr Butt reports advisory board honoraria from Bayer, outside the submitted work. Dr Petri and Dr McMurray are supported by a British Heart Foundation Centre of Research Excellence Grant (RE/18/6/34217). Dr Schou reports lecture fees from Novartis, Astra Zeneca, Novo Nordisk, and Boehringer Ingelheim.
PY - 2022
Y1 - 2022
N2 - BACKGROUND: Guideline-recommended disease-modifying pharmacological therapies for heart failure (HF) with reduced ejection fraction are underutilized, particularly among elderly patients. We studied the association of age in adherence and discontinuation of angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers (ACEi/ARB), β-blockers (BB), and mineralocorticoid receptor antagonists. METHODS AND RESULTS: Patients with a first heart failure diagnosis who had initiated ACEi/ARB and BB within 120 days of presentation were included from nationwide registries and divided into 3 age groups: <65 years (reference), 65 to 79, and ≥80. One-year median proportions of daily target doses were calculated. Adherence was estimated by the proportion of days covered. The 5-year risk of discontinuation was assessed with the Aalen-Johansen estimator. Discontinuation rates were evaluated using Multivariable Cox regression. Twenty-nine thousand four hundred eighty-two patients were included. Advancing age was associated with lower median proportions of daily target doses and adherence (ACEi/ARB 79.1%, 77.5%, and 69.4%; BB 79.1%, 78.6%, and 73.8%), in the <65, 65 to 79, and ≥80 age groups, respectively. Age ≥80 was associated with higher discontinuation rates (cumulative incidence, ACEi/ARB 41%, 44%, and 51%; BB 38%, 35%, and 39%; hazard ratio, ACEi/ARB 1.60 [95% CI, 1.51–1.69]; BB 1.33 [95% CI, 1.25–1.41]). The risk of mineralocorticoid receptor antagonists discontinuation differed little with age (50%, 54%, and 56%), although mineralocorticoid receptor antagonists initiation in the most elderly was less frequent (33%, 33%, and 22%). CONCLUSIONS: In a nationwide cohort of patients with heart failure, advanced age was associated with lower proportions of daily target doses, lower adherence, and higher discontinuation rates of ACEi/ARB and BBs. Focus on treatment adherence and optimal dosages among elderly patients with heart failure could improve outcomes.
AB - BACKGROUND: Guideline-recommended disease-modifying pharmacological therapies for heart failure (HF) with reduced ejection fraction are underutilized, particularly among elderly patients. We studied the association of age in adherence and discontinuation of angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers (ACEi/ARB), β-blockers (BB), and mineralocorticoid receptor antagonists. METHODS AND RESULTS: Patients with a first heart failure diagnosis who had initiated ACEi/ARB and BB within 120 days of presentation were included from nationwide registries and divided into 3 age groups: <65 years (reference), 65 to 79, and ≥80. One-year median proportions of daily target doses were calculated. Adherence was estimated by the proportion of days covered. The 5-year risk of discontinuation was assessed with the Aalen-Johansen estimator. Discontinuation rates were evaluated using Multivariable Cox regression. Twenty-nine thousand four hundred eighty-two patients were included. Advancing age was associated with lower median proportions of daily target doses and adherence (ACEi/ARB 79.1%, 77.5%, and 69.4%; BB 79.1%, 78.6%, and 73.8%), in the <65, 65 to 79, and ≥80 age groups, respectively. Age ≥80 was associated with higher discontinuation rates (cumulative incidence, ACEi/ARB 41%, 44%, and 51%; BB 38%, 35%, and 39%; hazard ratio, ACEi/ARB 1.60 [95% CI, 1.51–1.69]; BB 1.33 [95% CI, 1.25–1.41]). The risk of mineralocorticoid receptor antagonists discontinuation differed little with age (50%, 54%, and 56%), although mineralocorticoid receptor antagonists initiation in the most elderly was less frequent (33%, 33%, and 22%). CONCLUSIONS: In a nationwide cohort of patients with heart failure, advanced age was associated with lower proportions of daily target doses, lower adherence, and higher discontinuation rates of ACEi/ARB and BBs. Focus on treatment adherence and optimal dosages among elderly patients with heart failure could improve outcomes.
KW - adherence
KW - age
KW - discontinuation
KW - heart failure
KW - pharmacotherapy
U2 - 10.1161/JAHA.122.026187
DO - 10.1161/JAHA.122.026187
M3 - Journal article
C2 - 36172925
AN - SCOPUS:85139442051
VL - 11
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
SN - 2047-9980
IS - 19
M1 - e026187
ER -
ID: 324821544